Review Article
Volume 10 Issue 5 - 2021
Use of Blood, Urine or Saliva-based Biomarkers in the Diagnosis of Active Pulmonary Tuberculosis - Sample Type Matters
Ngiambudulu M Francisco1,2,3*
1Curso de Análises Clínicas, Departamento de Ciências da Saúde, Instituto Superior Politécnico Kangonjo, Luanda, Angola
2Curso de Enfermagem, Departamento de Ciências da Saúde, Instituto Superior Politécnico Kangonjo, Luanda, Angola
3Curso de Ciências Farmacêuticas, Departamento de Ciências da Saúde, Instituto Superior Politécnico Kangonjo, Luanda, Angola
*Corresponding Author: Ngiambudulu M. Francisco, Departamento de Ciências da Saúde, Instituto Superior Politécnico Kangonjo, Luanda, Angola.
Received: February 02, 2021; Published: April 30, 2021


Novel molecular diagnostic tools that are rapid, accurate, cost-effective, and could be used at point-of-care are urgently required if we are to achieve the goals of the End TB Strategy and reduce TB incidence by 90% by 2035. Early and rapid diagnosis of TB can significantly improve therapeutic outcomes, patient survival rates and reduce recurrence. Studies have examined blood, urine, saliva and sputum to identify new TB biomarker candidates. However, no comparative evaluation of all four fluids as a diagnostic tool to identify active and latent TB has been reported.

In the present paper, I peer-reviewed publications from PubMed databases in all languages between 2000 - April 1, 2018.

Identifying a sample type, with appropriate microbial, immunologic or molecular biomarkers to accurately diagnose active TB or latent TB, particularly if the sample was easier to collect, such as saliva; offers a unique opportunity to reduce discomfort in patients via the provision of a noninvasive TB detection method.

With its ease of access, processing and the invasiveness of collection procedures for TB molecular diagnosis, putting effort and resources into the saliva biomarker investigation may yield a point-of-care molecular diagnostic test that could revolutionize the TB field.


Keywords: Infection; Mycobacterium tuberculosis; Biomarkers; Molecular Diagnosis; Point-of-Care


  1. WHO: Global Tuberculosis Report. Geneva: World Health Organization 2017, Licence: CC BY-NCSA 3.0 IGO (2017): 1-262.
  2. Francisco NM., et al. “Diagnostic accuracy of a selected signature gene set that discriminates active pulmonary tuberculosis and other pulmonary diseases”. Journal of Infection6 (2017): 499-510.
  3. Parrish NM and Carroll KC. “Role of the clinical mycobacteriology laboratory in diagnosis and management of tuberculosis in low-prevalence settings”. Journal of Clinical Microbiology 3 (2011): 772-776.
  4. Davies PD and Pai M. “The diagnosis and misdiagnosis of tuberculosis”. International Journal of Tuberculosis and Lung Disease 11 (2008): 1226-1234.
  5. Adekambi T., et al. “Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response”. Journal of Clinical Investigation 9 (2015): 3723.
  6. Nyendak MR., et al. “New diagnostic methods for tuberculosis”. Current Opinion in Infectious Diseases - LWW Journals 2 (2009): 174-182.
  7. Thillai M., et al. “Interferon-gamma release assays for tuberculosis: current and future applications”. Expert Review of Respiratory Medicine 1 (2014): 67-78.
  8. Meier T., et al. “Sensitivity of a new commercial enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberculosis in clinical practice”. European Journal of Clinical Microbiology and Infectious Diseases 8 (2005): 529-536.
  9. Janssens JP., et al. “Quantitative scoring of an interferon-gamma assay for differentiating active from latent tuberculosis”. European Respiratory Journal 4 (2007): 722-728.
  10. Denkinger CM., et al. “Gamma interferon release assay for monitoring of treatment response for active tuberculosis: an explosion in the spaghetti factory”. Journal of Clinical Microbiology 2 (2013): 607-610.
  11. Zelles T., et al. “Concise review. Saliva and growth factors: the fountain of youth resides in us all”. Journal of Dental Research 74 (1995): 1826-1832.
  12. Rehak NN., et al. “Biochemical composition and electrolyte balance of "unstimulated" whole human saliva”. Clinical Chemistry and Laboratory Medicine 4 (2000): 335-343.
  13. Green C., et al. “Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods”. The Lancet Infectious Diseases8 (2009): 505-511.
  14. Gupta-Wright A., et al. “Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis”. BMC Medicine 53 (2016): 53.
  15. Rueda CM., et al. “Characterization of CD4 and CD8 T cells producing IFN-gamma in human latent and active tuberculosis”. Tuberculosis6 (2010): 346-353.
  16. Aas JA., et al. “Defining the normal bacterial flora of the oral cavity”. Journal of Clinical Microbiology 11 (2005): 5721-5732.
  17. Bonne NJ and Wong DT. “Salivary biomarker development using genomic, proteomic and metabolomic approaches”. Genome Medicine 10 (2012): 82.
  18. Park NJ., et al. “Characterization of RNA in saliva”. Clinical Chemistry 6 (2006): 988-994.
  19. Hu S., et al. “Human saliva proteome analysis”. Annals of the New York Academy of Sciences 1098 (2007): 323-329.
  20. Mager DL., et al. “The salivary microbiota as a diagnostic indicator of oral cancer: A descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects”. Journal of Translational Medicine 3 (2005): 27.
  21. Amado LA., et al. “Detection of hepatitis A, B, and C virus-specific antibodies using oral fluid for epidemiological studies”. Memórias do Instituto Oswaldo Cruz 2 (2006): 149-155.
  22. Zhang L., et al. “Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer”. Gastroenterology3 (2010): e941-947.
  23. Li Y., et al. “Salivary transcriptome diagnostics for oral cancer detection”. Clinical Cancer Research24 (2004): 8442-8450.
  24. Hu S., et al. “Salivary proteomics for oral cancer biomarker discovery”. Clinical Cancer Research19 (2008): 6246-6252.
  25. Streckfus C., et al. “The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: A preliminary study”. Clinical Cancer Research6 (2000): 2363-2370.
  26. Yoshizawa JM., et al. “Salivary biomarkers: toward future clinical and diagnostic utilities”. Clinical Microbiology Reviews 4 (2013): 781-791.
  27. Miller SM. “Saliva testing--a nontraditional diagnostic tool”. Clinical Laboratory Science Journal 1 (1994): 39-44.
  28. WHO: International Programme on Chemical Safety. Biomarkers in Risk Assessment: Validity and Validation”. In: Environmental Health Criteria 222.
  29. Silberring J and Ciborowski P. “Biomarker discovery and clinical proteomics”. TrAC Trends in Analytical Chemistry2 (2010): 128-140.
  30. Kurian S., et al. “Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers”. International Immunopharmacology 7 (2007): 1948-1960.
  31. Wagner PD., et al. “Challenges for biomarkers in cancer detection”. Annals of the New York Academy of Sciences 1022 (2004): 9-16.
  32. Bonassi S., et al. “Validation of biomarkers as early predictors of disease”. Mutation Research 480-481 (2001): 349-358.
  33. Petersen C and Round JL. “Defining dysbiosis and its influence on host immunity and disease”. Cell Microbiology7 (2014): 1024-1033.
  34. Backhed F., et al. “Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications”. Cell Host Microbe5 (2012): 611-622.
  35. Trompette A., et al. “Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis”. Nature Medicine 2 (2014): 159-166.
  36. Hsiao EY., et al. “Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders”. Cell 7 (2013): 1451-1463.
  37. Garrett WS. “Cancer and the microbiota”. Science6230 (2015): 80-86.
  38. Cui Z., et al. “Complex sputum microbial composition in patients with pulmonary tuberculosis”. BMC Microbiology 12 (2012): 276.
  39. Cheung MK., et al. “Sputum microbiota in tuberculosis as revealed by 16S rRNA pyrosequencing”. PLoS ONE1 (2013): e54574.
  40. Luo M., et al. “Alternation of Gut Microbiota in Patients with Pulmonary Tuberculosis”. Frontiers in Physiology 822 (2017): 822.
  41. Wu J., et al. “Sputum microbiota associated with new, recurrent and treatment failure tuberculosis”. PLoS ONE12 (2013): e83445.
  42. Winglee K., et al. “Aerosol Mycobacterium tuberculosis infection causes rapid loss of diversity in gut microbiota”. PLoS ONE5 (2014): e97048.
  43. Khan N., et al. “Alteration in the Gut Microbiota Provokes Susceptibility to Tuberculosis”. Frontiers in Immunology 7 (2016): 529.
  44. Majlessi L., et al. “Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis”. Mucosal Immunology 5 (2017): 1178-1189.
  45. Tobin DM., et al. “Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections”. Cell 3 (2012): 434-446.
  46. Zhang G., et al. “A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans”. Nature Communications 1 (2018): 85.
  47. Benson AK., et al. “Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors”. Proceedings of the National Academy of Sciences of the United States of America 44 (2010): 18933-18938.
  48. Manzo VE and Bhatt AS. “The human microbiome in hematopoiesis and hematologic disorders”. Blood3 (2015): 311-318.
  49. David LA., et al. “Diet rapidly and reproducibly alters the human gut microbiome”. Nature7484 (2014): 559-563.
  50. Hu Z., et al. “Revealing Missing Human Protein Isoforms Based on Ab Initio Prediction, RNA-seq and Proteomics”. Scientific Reports 5 (2015): 10940.
  51. Haas CT., et al. “Diagnostic 'omics' for active tuberculosis”. BMC Medicine 14 (2016): 37.
  52. Mistry R., et al. “Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis”. Journal of Infectious Diseases3 (2007): 357-365.
  53. Bloom CI., et al. “Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers”. PLoS ONE8 (2013): e70630.
  54. Koth LL., et al. “Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis”. American Journal of Respiratory and Critical Care Medicine 10 (2011): 1153-1163.
  55. Maertzdorf J., et al. “Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis”. PLoS ONE10 (2011): e26938.
  56. Maertzdorf J., et al. “Common patterns and disease-related signatures in tuberculosis and sarcoidosis”. Proceedings of the National Academy of Sciences of the United States of America20 (2012): 7853-7858.
  57. Ottenhoff TH., et al. “Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis”. PLoS ONE9 (2012): e45839.
  58. Stern JN., et al. “Molecular signatures distinguishing active from latent tuberculosis in peripheral blood mononuclear cells, after in vitro antigenic stimulation with purified protein derivative of tuberculin (PPD) or Candida: a preliminary report”. Immunologic Research 1 (2009): 1-12.
  59. Cliff JM., et al. “Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response”. The Journal of Infectious Diseases 1 (2013): 18-29.
  60. Bloom CI., et al. “Detectable changes in the blood transcriptome are present after two weeks of antituberculosis therapy”. PLoS ONE10 (2012): e46191.
  61. McHugh L., et al. “A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts”. PLOS Medicine 12 (2015): e1001916.
  62. Berry MP., et al. “An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis”. Nature7309 (2010): 973-977.
  63. Kaforou M., et al. “Detection of tuberculosis in HIV-infected and -uninfected African adults using whole blood RNA expression signatures: a case-control study”. PLOS Medicine 10 (2013): e1001538.
  64. Walter ND., et al. “Blood Transcriptional Biomarkers for Active Tuberculosis among Patients in the United States: a Case-Control Study with Systematic Cross-Classifier Evaluation”. Journal of Clinical Microbiology 2 (2016): 274-282.
  65. Maertzdorf J., et al. “Concise gene signature for point-of-care classification of tuberculosis”. EMBO Molecular Medicine 2 (2016): 86-95.
  66. Sweeney TE., et al. “Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis”. The Lancet Respiratory Medicine 3 (2016): 213-224.
  67. Lau SK., et al. “Metabolomic Profiling of Plasma from Patients with Tuberculosis by Use of Untargeted Mass Spectrometry Reveals Novel Biomarkers for Diagnosis”. Journal of Clinical Microbiology 12 (2015): 3750-3759.
  68. Weiner J., et al. “Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients”. PLoS ONE7 (2012): e40221.
  69. Frediani JK., et al. “Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study”. PLoS ONE10 (2014): e108854.
  70. Du Preez I and Loots DT. “New sputum metabolite markers implicating adaptations of the host to Mycobacterium tuberculosis, and vice versa”. Tuberculosis3 (2013): 330-337.
  71. Monteiro MS., et al. “Metabolomics analysis for biomarker discovery: advances and challenges”. Current Medicinal Chemistry 2 (2013): 257-271.
  72. Vuckovic D. “Improving metabolome coverage and data quality: advancing metabolomics and lipidomics for biomarker discovery”. Chemical Communications50 (2018): 6728-6749.
  73. Graves PR and Haystead TA. “Molecular biologist's guide to proteomics”. Microbiology and Molecular Biology Reviews 1 (2002): 39-63.
  74. Agranoff D., et al. “Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum”. Lancet9540 (2006): 1012-1021.
  75. Sandhu G., et al. “Discriminating active from latent tuberculosis in patients presenting to community clinics”. PLoS ONE5 (2012): e38080.
  76. Zhang X., et al. “A proteomics approach to the identification of plasma biomarkers for latent tuberculosis infection”. Diagnostic Microbiology and Infectious Disease 4 (2014): 432-437.
  77. Wang C., et al. “Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis”. Scientific Report 5 (2015): 15615.
  78. Achkar JM., et al. “Host Protein Biomarkers Identify Active Tuberculosis in HIV Uninfected and Co-infected Individuals”. EBio Medicine9 (2015): 1160-1168.
  79. Venkatesh A., et al. “A Perspective on Proteomics of Infectious Diseases”. Proteomics Clinical Applications (2017).
  80. Noble WS and MacCoss MJ. “Computational and statistical analysis of protein mass spectrometry data”. PLOS Computational Biology 1 (2012): e1002296.
  81. Bordelon H., et al. “Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: Application for transrenal Mycobacterium tuberculosis DNA detection”. The Journal of Microbiological Methods 136 (2017): 65-70.
  82. Young BL., et al. “The identification of tuberculosis biomarkers in human urine samples”. European Respiratory Journal 6 (2014): 1719-1729.
  83. Kashino SS., et al. “Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules”. Clinical and Experimental Immunology 1 (2008): 56-62.
  84. Pollock NR., et al. “Validation of Mycobacterium tuberculosis Rv1681 protein as a diagnostic marker of active pulmonary tuberculosis”. Journal of Clinical Microbiology 5 (2013): 1367-1373.
  85. Choudhry V and Saxena RK. “Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients”. European Journal of Clinical Microbiology and Infectious Diseases 1 (2002): 1-5.
  86. Kim SH., et al. “Identification of Mycobacterial Antigens in Human Urine by Use of Immunoglobulin G Isolated from Sera of Patients with Active Pulmonary Tuberculosis”. Journal of Clinical Microbiology 6 (2016): 1631-1637.
  87. Wang J., et al. “Identification of potential urine proteins and microRNA biomarkers for the diagnosis of pulmonary tuberculosis patients”. Emerging Microbes and Infections 1 (2018): 63.
  88. Hamasur B., et al. “Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine”. The Journal of Microbiological Methods 1 (2001): 41-52.
  89. Chatterjee D. “The mycobacterial cell wall: structure, biosynthesis and sites of drug action”. Current Opinion in Chemical Biology4 (1997): 579-588.
  90. Brennan PJ. “Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis”. Tuberculosis1-3 (2003): 91-97.
  91. Nigou J., et al. “Lipoarabinomannans: from structure to biosynthesis”. Biochimie1-2 (2003): 153-166.
  92. Dheda K., et al. “Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples”. PLoS ONE3 (2010): e9848.
  93. Minion J., et al. “Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis”. European Respiratory Journal 6 (2011): 1398-1405.
  94. Bain MD., et al. “Contribution of gut bacterial metabolism to human metabolic disease”. Lancet8594 (1988):1078-1079.
  95. Nicholls AW., et al. “NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats”. Chemical Research in Toxicology 11 (2003): 1395-1404.
  96. Dettmer K., et al. “Mass spectrometry-based metabolomics”. Mass Spectrometry Reviews 1 (2007): 51-78.
  97. Bollard ME., et al. “NMR-based metabonomic approaches for evaluating physiological influences on biofluid composition”. NMR Biomed3 (2005): 143-162.
  98. Kim K., et al. “Urine metabolomics analysis for kidney cancer detection and biomarker discovery”. Molecular and Cellular Proteomics 8.3 (2009): 558-570.
  99. Wang-Sattler R., et al. “Novel biomarkers for pre-diabetes identified by metabolomics”. Molecular Systems Biology 8 (2012): 615.
  100. Rhee EP and Gerszten RE. “Metabolomics and cardiovascular biomarker discovery”. Clinical Chemistry 1 (2012): 139-147.
  101. Beisel WR. “Metabolic response to infection”. Annual Review of Medicine 26 (1975): 9-20.
  102. Zhang A., et al. “Modern analytical techniques in metabolomics analysis”. Analyst2 (2012): 293-300.
  103. Vinayavekhin N., et al. “Exploring Disease through Metabolomics”. ACS Chemical Biology 1 (2010): 91-103.
  104. Mahapatra S., et al. “A metabolic biosignature of early response to anti-tuberculosis treatment”. BMC Infectious Diseases 14 (2014): 53.
  105. Adachi J., et al. “The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins”. Genome Biology9 (2006): R80.
  106. Husi H., et al. “Proteomic analysis of urinary upper gastrointestinal cancer markers”. Proteomics Clinical Applications 5-6 (2011): 289-299.
  107. Khan A and Packer NH. “Simple urinary sample preparation for proteomic analysis”. Journal of Proteome Research 10 (2006): 2824-2838.
  108. Good DM., et al. “Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future”. Journal of Proteome Research 12 (2007): 4549-4555.
  109. Cui S., et al. “Megalin/gp330 mediates uptake of albumin in renal proximal tubule”. American Journal of Physiology 4-2 (1996): F900-907.
  110. Pisitkun T., et al. “Identification and proteomic profiling of exosomes in human urine”. Proceedings of the National Academy of Sciences of the United States of America36 (2004): 13368-13373.
  111. Castagna A., et al. “Exploring the hidden human urinary proteome via ligand library beads”. Journal of Proteome Research 6 (2005): 1917-1930.
  112. Pieper R., et al. “Characterization of the human urinary proteome: a method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots”. Proteomics4 (2004): 1159-1174.
  113. Sun W., et al. “Human urine proteome analysis by three separation approaches”. Proteomics 18 (2005): 4994-5001.
  114. Wang L., et al. “Concanavalin A-captured glycoproteins in healthy human urine”. Molecular and Cellular Proteomics 3 (2006): 560-562.
  115. Haraldsson B and Sorensson J. “Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier”. News in Physiological Sciences 1 (2004): 7-10.
  116. Peng J and Gygi SP. “Proteomics: the move to mixtures”. Journal of Mass Spectrometry 10 (2001): 1083-1091.
  117. Thongboonkerd V. “Proteomics in nephrology: current status and future directions”. The American Journal of Nephrology 3 (2004): 360-378.
  118. Maunsbach AB. “Absorption of I125-labeled homologous albumin by rat kidney proximal tubule cells. A study of microperfused single proximal tubules by electron microscopic autoradiography and histochemistry. 1966”. Journal of the American Society of Nephrology 2 (1997): 323-351.
  119. Burne MJ., et al. “Fractional clearance of high molecular weight proteins in conscious rats using a continuous infusion method”. Kidney International 1 (1999): 261-270.
  120. Batuman V., et al. “Myeloma light chains are ligands for cubilin (gp280)”. American Journal of Physiology 2-(1998): F246-254.
  121. Christensen EI and Gburek J. “Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology”. Pediatric Nephrology 7 (2004): 714-721.
  122. Wu J., et al. “Urinary proteomics as a novel tool for biomarker discovery in kidney diseases”. Journal of Zhejiang University Science B 4 (2010): 227-237.
  123. Paris L., et al. “Urine lipoarabinomannan glycan in HIV-negative patients with pulmonary tuberculosis correlates with disease severity”. Science Translational Medicine 420 (2017).
  124. Pollock N., et al. “Discovery of a unique Mycobacterium tuberculosis protein through proteomic analysis of urine from patients with active tuberculosis”. Microbes and Infection 17 (2018): 30239-30233.
  125. Schipper RG., et al. “Saliva as research material: biochemical, physicochemical and practical aspects”. Archives of Oral Biology 12 (2007): 1114-1135.
  126. Gustafsson A., et al. “Detection of suPAR in the Saliva of Healthy Young Adults: Comparison with Plasma Levels”. Biomarker Insights 6 (2011): 119-125.
  127. Marais BJ and Pai M. “New approaches and emerging technologies in the diagnosis of childhood tuberculosis”. Paediatric Respiratory Reviews 2 (2007): 124-133.
  128. Chegou NN., et al. “Evaluation of adapted whole-blood interferon-gamma release assays for the diagnosis of pleural tuberculosis”. Respiration2 (2008): 131-138.
  129. Munk ME., et al. “Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis”. The Journal of Infectious Diseases 1 (2001): 175-176.
  130. Jacobs R., et al. “Diagnostic Potential of Novel Salivary Host Biomarkers as Candidates for the Immunological Diagnosis of Tuberculosis Disease and Monitoring of Tuberculosis Treatment Response”. PLoS ONE 8 (2016): e0160546.
  131. Haffajee AD and Socransky SS. “Microbial etiological agents of destructive periodontal diseases”. Periodontology 2000 5 (1994): 78-111.
  132. Park NJ., et al. “Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection”. Clinical Cancer Research 17 (2009): 5473-5477.
  133. Hu S., et al. “Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome”. Arthritis and Rheumatism11 (2007): 3588-3600.
  134. Lee YH., et al. “Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma”. Journal of Molecular Medicine4 (2012): 427-434.
  135. Brinkmann O and Wong DT. “Salivary transcriptome biomarkers in oral squamous cell cancer detection”. Advances in Clinical Chemistry 55 (2011): 21-34.
  136. Eguchi J IK., et al. “PCR method is essential for detecting Mycobacterium tuberculosis in oral cavity samples”. Oral Microbiology and Immunology 3 (2003): 156-159.
  137. Eguchi J., et al. “PCR method is essential for detecting Mycobacterium tuberculosis in oral cavity samples”. Oral Microbiology and Immunology 3 (2003): 156-159.
  138. Al Kawas S., et al. “Potential uses of human salivary protein and peptide analysis in the diagnosis of disease”. Archives of Oral Biology 1 (2012): 1-9.
  139. Spielmann N and Wong DT. “Saliva: diagnostics and therapeutic perspectives”. Oral Diseases 4 (2011): 345-354.
  140. Streckfus C and Bigler L. “The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study”. Advances in Dental Research 1 (2005): 17-24.
  141. Genco RJ., et al. “A proposed model linking inflammation to obesity, diabetes, and periodontal infections”. Journal of Periodontology 11 (2005): 2075-2084.
  142. Huang CM. “Comparative proteomic analysis of human whole saliva”. Archives of Oral Biology 12 (2004): 951-962.
  143. St John MA., et al. “Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma”. Archives of Otolaryngology--Head and Neck Surgery 8 (2004): 929-935.
  144. Rao PV., et al. “Proteomic identification of salivary biomarkers of type-2 diabetes”. Journal of Proteome Research 1 (2009): 239-245.
  145. Landrum ML., et al. “Usefulness of a rapid human immunodeficiency virus-1 antibody test for the management of occupational exposure to blood and body fluid”. Infection Control and Hospital Epidemiology9 (2005): 768-774.
  146. Jacobs R., et al. “Host biomarkers detected in saliva show promise as markers for the diagnosis of pulmonary tuberculosis disease and monitoring of the response to tuberculosis treatment”. Cytokine 81 (2016): 50-56.
  147. Namuganga AR., et al. “Suitability of saliva for Tuberculosis diagnosis: comparing with serum”. BMC Infectious Diseases 1 (2017): 600.
  148. Anderson ST., et al. “Diagnosis of childhood tuberculosis and host RNA expression in Africa”. The New England Journal of Medicine 18 (2014): 1712-1723.
  149. Cai Y., et al. “Increased complement C1q level marks active disease in human tuberculosis”. PLoS ONE3 (2014): e92340.
  150. Dawany N., et al. “Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection”. PLoS ONE2 (2014): e89925.
  151. Verhagen LM., et al. “A predictive signature gene set for discriminating active from latent tuberculosis in Warao Amerindian children”. BMC Genomics 14 (2013): 74.
  152. Lesho E., et al. “Transcriptional responses of host peripheral blood cells to tuberculosis infection”. Tuberculosis 5 (2011): 390-399.
  153. Maertzdorf J., et al. “Human gene expression profiles of susceptibility and resistance in tuberculosis”. Genes and Immunity 1 (2011): 15-22.
  154. Lu C., et al. “Novel biomarkers distinguishing active tuberculosis from latent infection identified by gene expression profile of peripheral blood mononuclear cells”. PLoS ONE8 (2011): e24290.
  155. Jacobsen M., et al. “Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis”. Journal of Molecular Medicine6 (2007): 613-621.
  156. Zhou A., et al. “Metabolomics specificity of tuberculosis plasma revealed by (1)H NMR spectroscopy”. Tuberculosis 3 (2015): 294-302.
  157. Feng S., et al. “Analysis of serum metabolic profile by ultra-performance liquid chromatography-mass spectrometry for biomarkers discovery: application in a pilot study to discriminate patients with tuberculosis”. Chinese Medical Journal 2 (2015): 159-168.
  158. Zhou A., et al. “Application of (1)h NMR spectroscopy-based metabolomics to sera of tuberculosis patients”. Journal of Proteome Research 10 (2013): 4642-4649.
  159. Che N., et al. “Decreased serum 5-oxoproline in TB patients is associated with pathological damage of the lung”. Clinica Chimica Acta 423 (2013): 5-9.
  160. Liu J., et al. “Comparative proteomic analysis of serum diagnosis patterns of sputum smear-positive pulmonary tuberculosis based on magnetic bead separation and mass spectrometry analysis”. International Journal of Clinical and Experimental Medicine 2 (2015): 2077-2085.
  161. Xu D., et al. “Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-dimensional LC-MS/MS”. Proteomics1 (2015): 58-67.
  162. Xu DD., et al. “Discovery and identification of serum potential biomarkers for pulmonary tuberculosis using iTRAQ-coupled two-dimensional LC-MS/MS”. Proteomics2-3 (2014): 322-331.
  163. Song SH., et al. “Proteomic profiling of serum from patients with tuberculosis”. Annals of Laboratory Medicine 5 (2014): 345-353.
  164. Nahid P., et al. “Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis”. Tuberculosis 3 (2014): 187-196.
  165. Liu J., et al. “The discovery and identification of a candidate proteomic biomarker of active tuberculosis”. BMC Infectious Diseases 13 (2013): 506.
  166. De Groote MA NP., et al. “Elucidating Novel Serum Biomarkers Associated with Pulmonary Tuberculosis Treatment”. PLoS ONE4 (2013): e61002.
  167. Zhang J., et al. “Diagnostic serum proteomic analysis in patients with active tuberculosis”. Clinica Chimica Acta 9-10 (2012): 883-887.
  168. Liu JY., et al. “New serum biomarkers for detection of tuberculosis using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry”. Clinical Chemistry and Laboratory Medicine 10 (2011): 1727-1733.
  169. Deng C., et al. “Establishing a serologic decision tree model of extrapulmonary tuberculosis by MALDI-TOF MS analysis”. Diagnostic Microbiology and Infectious Disease 2 (2011): 144-150.
  170. Tanaka T., et al. “Identification of tuberculosis-associated proteins in whole blood supernatant”. BMC Infectious Diseases 11 (2011): 71.
  171. Liu Q., et al. “Serum protein profiling of smear-positive and smear-negative pulmonary tuberculosis using SELDI-TOF mass spectrometry”. Lung 1 (2010): 15-23.
Citation: Ngiambudulu M Francisco., et al “Use of Blood, Urine or Saliva-based Biomarkers in the Diagnosis of Active Pulmonary Tuberculosis - Sample Type Matters”. EC Pulmonology and Respiratory Medicine 10.5 (2021): 48-69.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

June Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the June issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before July 06, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to